High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 181-183

  Quan Jr , Walter D Y ^a,c   Quan, Francine M ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Famotidine; Interleukin 2; Kidney cancer; Lymphokine activated killer cells

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; FAMOTIDINE; INTERLEUKIN 2;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CENTER; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; FEVER; HEART ATRIUM ARRHYTHMIA; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; KIDNEY METASTASIS; LUNG EDEMA; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; CYTOKINE-INDUCED KILLER CELLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-2; TREATMENT OUTCOME;

EID: 66249134923     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0564     Document Type: Article

References (19)

1. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokineactivated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823. (Pubitemid 12074218)
2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 therapy in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl 1) : S55. (Pubitemid 30117639)
3. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 2008; 113: 293.
4. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486. (Pubitemid 19098144)
5. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694.
6. Quan WDY, Jr, Quan FM. Outpatient experience with moderate dose bolus interleukin-2 in metastatic malignant melanoma and kidney cancer. J Immunother 2003; 26: 286. (Pubitemid 36686897)
7. Quan WDY, Jr, Dean GE, Lieskovsky G, et al. Phase II study of low-dose cyclophosphamide and intravenous interleukin- 2 in metastatic renal cancer. Investigational New Drugs 1994; 12: 35. (Pubitemid 24209063)
8. Tsunoda T, Tanimura H, Yamaue H, et al. In-vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmac 1992; 14: 75.
9. Therasse P, Arbuck SG, Eisenhauer EA, al. New guidelines to evaluate the response to treatment in solid tumors. 2000; JNCI 92: 205. (Pubitemid 30099779)
10. Quan W, Jr, Ramirez M, Taylor WC, et al. Continuous infusion plus pulse interleukin-2 and famotidine in melanoma. Cancer Biother Radiopharm 2004; 19: 770. (Pubitemid 40279587)
11. Quan WDY, Jr, Ramirez M, Taylor C, et al. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother Radiopharm 2005; 20: 11. (Pubitemid 40478516)
12. Moertel CG. On lymphokines, cytokines, and breakthroughs. JAMA 1986; 256: 3141. (Pubitemid 17045832)
13. Fernandez-Rodriguez R, de Argumedo GL, Mane JM, et al. High-dose interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 6797. (Pubitemid 46190278)
14. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991; 9: 1233.
15. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid highdose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 1997; 12: 5. (Pubitemid 27150025)
16. Yang JC, Rosenberg SA. An ongoing prospective, randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell carcinoma. Cancer J Sci Am 1997; 3 (Suppl 1) : S79. (Pubitemid 127698066)
17. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. 1994; JAMA 271: 907. (Pubitemid 24083215)
18. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective, randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622. (Pubitemid 23120507)
19. Quan WDY, Jr, Vinogradov M, Quan FM, et al. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm 2006; 21: 513.